ImmunityBio Inc Ordinary Shares IBRX 深 沪
等待开盘 08-02 09:30:00 美东时间
2.375
-0.085
-3.46%
华盛通- 最 高2.42
- 今 开2.37
- 成交量 470.10万股
- 最 低 2.335
- 昨 收 2.46
- 总市值 20.97亿
- 52周最高 7.48
- 市盈率 静 --
- 换手率 0.53%
- 52周最低 1.83
- 委 比 4.52%
- 总股本 8.83亿
- 历史最高 45.42
- 量 比 0.63
- 振 幅 3.46%
- 历史最低 0.93
- 每 手 1
- 风险率 0.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ImmunityBio secures $80M financing
ImmunityBio (NASDAQ:IBRX) has secured new financing to provide further working capital and support its ongoing business operations. The company entered into a securities purchase agreement with two in...
07-25 18:10
ImmunityBio reports Q2 revenue above consensus
ImmunityBio press release (NASDAQ:IBRX): Q2 revenue of $26.4M (+60.0% Q/Q) beats by $4.45M. More on ImmunityBio ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval ImmunityBio: Hi...
07-25 18:07
孙正义：《洛杉矶时报》将上市
《洛杉矶时报》老板帕特里克・孙正义（Patrick Soon-Shiong）周一在接受电视采访时表示，这家有着 143 年历史的报纸计划在未来一年内上市，旨...
07-22 16:29
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper
Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year-old newspaper public within the next year.
07-22 14:36
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the di...
07-09 20:30
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target
D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $30 price target.
07-08 19:19
Reported Earlier, ImmunityBio Gains UK Marketing Authorization for ANKTIVA With Bacillus Calmette-Guérin In Bladder Cancer, Expanding Breakthrough Therapy Beyond U.S
ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, helping eliminate cancerAlready approved in the U.S. and designated as
07-08 14:29
ImmunityBio Approves 2025 Equity Incentive Plan
An update from ImmunityBio ( ($IBRX) ) is now available. On June 18, 2025, Immu...
06-21 05:11
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- Equity Insider News Commentary – The 2025 ASCO Annual Meeting has wrap...
06-12 22:00
美股大行评级 | 花旗首予霸王茶姬"买入"评级，CrowdStrike、达乐公司、Guidewire Software、Snowflake获多家机构上调评级和目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137304602125590529.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Wolfe Research：维持Cheche Group(CCG)"跑赢大市"评级，目标价从335美元升至350美元</p> <p>• HC Wainwright & Co.：上调AnaptysBio(ANAB)
06-05 09:42
